In this issue
In this insightful new interview, key opinion leader Talha Munir reviews the current landscape of chronic lymphocytic leukaemia (CLL), and delves into interim analysis results from the AMPLIFY study with acalabrutinib–venetoclax ± obinutuzumab, 5-year data from the SEQUOIA study with zanubrutinib, and updated data from the BRUIN CLL-321 study with pirtobrutinib.
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Latest articles
All articles


We’ve noticed you’re accessing
from North/South America.
from North/South America.
